Cargando…

A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor

Background: Chimeric antigen receptor (CAR) T-cell therapy is practical in treating cancers of hematopoietic origin, but of that in solid tumors compromises efficacy for the loss of the antigen recognized by the CAR. However, dendritic cell (DC)/tumor fusion vaccines present a spectrum of known or u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Shuyang, Ding, Ziqiang, Gao, Li, Hammock, Bruce D., Huang, Xianing, Xu, Zhi Ping, Wang, Xuan, Cheng, Qihong, Mo, Fengzhen, Shi, Wei, Xie, Shenxia, Liu, Aiqun, Li, Haixia, Yang, Xiaomei, Lu, Xiaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526666/ https://www.ncbi.nlm.nih.gov/pubmed/37771772 http://dx.doi.org/10.7150/thno.84946

Ejemplares similares

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
por: Sun, Shuyang, et al.
Publicado: (2021)

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
por: Mo, Fengzhen, et al.
Publicado: (2021)

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy
por: Zhu, Lichen, et al.
Publicado: (2020)

Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots
por: Wang, Wu, et al.
Publicado: (2019)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects
por: Xie, Shenxia, et al.
Publicado: (2021)

Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
por: Su, Qianling, et al.
Publicado: (2022)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

Opportunities and Challenges for Antibodies against Intracellular Antigens
por: Yang, Xiaofeng, et al.
Publicado: (2019)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

Nanobody-based CAR-T cells for cancer immunotherapy
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022)

In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice
por: Ding, Ziqiang, et al.
Publicado: (2020)

CAMEL NANOBODY-BASED B7-H3 CAR-T CELLS WITH HIGH EFFICACY AGAINST SOLID TUMORS
por: Li, Dan, et al.
Publicado: (2023)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions
por: Koido, Shigeo, et al.
Publicado: (2010)

Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity
por: Huang, Yingying, et al.
Publicado: (2017)

Nanobody Based Dual Specific CARs
por: De Munter, Stijn, et al.
Publicado: (2018)

Fusion expression of nanobodies specific for the insecticide fipronil on magnetosomes in Magnetospirillum gryphiswaldense MSR-1
por: Wu, Sha, et al.
Publicado: (2021)

Dendritic-Tumor Fusion Cell-Based Cancer Vaccines
por: Koido, Shigeo
Publicado: (2016)

Construction of a T7 phage display nanobody library for bio-panning and identification of chicken dendritic cell-specific binding nanobodies
por: Xu, Hai, et al.
Publicado: (2022)

A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects
por: Wang, Wu, et al.
Publicado: (2021)

Fusions between dendritic cells and whole tumor cells as anticancer vaccines
por: Koido, Shigeo, et al.
Publicado: (2013)

Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice
por: Lutz, Emi A, et al.
Publicado: (2022)

Generation of a CD70-Specific Fusion Nanobody with IgG Recruiting Capacity for Tumor Killing
por: Liu, Chang, et al.
Publicado: (2023)

IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
por: Fanuzzi, Mia, et al.
Publicado: (2023)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines
por: Koido, Shigeo, et al.
Publicado: (2011)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
por: Temple, William C, et al.
Publicado: (2023)

Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers
por: Yang, Xiaomei, et al.
Publicado: (2019)

Simultaneous selection of nanobodies for accessible epitopes on immune cells in the tumor microenvironment
por: Sekar, Thillai V., et al.
Publicado: (2023)

The Establishment of Dendritic Cell-Tumor Fusion Vaccines for Hormone Refractory Prostate Cancer Cell
por: Kim, Tae-Beom, et al.
Publicado: (2010)

Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells
por: Koido, Shigeo, et al.
Publicado: (2010)

Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine
por: MOU, YONGBIN, et al.
Publicado: (2013)

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer
por: Zhang, Lei, et al.
Publicado: (2022)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia
por: Cheng, Jiali, et al.
Publicado: (2023)

The tumor vasculature an attractive CAR T cell target in solid tumors
por: Akbari, Parvin, et al.
Publicado: (2019)

EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
por: Li, Dan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cfe149k3tj10dkmc63pil6i2qf